Journal
MEDICAL SCIENCE MONITOR
Volume 24, Issue -, Pages 8831-8839Publisher
INT SCIENTIFIC INFORMATION, INC
DOI: 10.12659/MSM.910932
Keywords
Drug Resistance; Ovarian Neoplasms; Paclitaxel; RNA; Long Noncoding
Categories
Funding
- Outstanding Scientific Fund of Shengjing Hospital [201705]
Ask authors/readers for more resources
Background: Epithelial ovarian cancer (EOC) has a high mortality rate and is a common malignant tumor of women, seriously impairing health. Chemoresistance is one of the major causes of poor prognosis. Therefore, analyzing the molecular mechanism of paclitaxel resistance has great significance. Material/Methods: We analyzed aberrantly expressed IncRNAs in chemoresistant EOC cells by microarray and confirmed LINC01118 expression by real-time PCR. The paclitaxel sensitivity alternation was analyzed by MTS, flow cytometry, and Transwell assay, while wound healing assays were performed to assess apoptosis, migration, and invasion in vitro. The interaction between LINC01118 and miR-134 was confirmed by luciferase assay. Results: LINC01118 was highly expressed in EOC tissues and chemoresistant cells. Biological function experiments showed LINC01118 could facilitate paclitaxel resistance and promote migration and invasion while inhibiting apoptosis of EOC cells. Moreover, LINC01118 targets miR-134 and then affects ABCC1 expression. Conclusions: LINC01118 acted as an oncogene and modulated EOC paclitaxel sensitivity by regulating miR-134/ABCC1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available